E7070

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Breast Cancer

Conditions

Metastatic Breast Cancer

Trial Timeline

Dec 1, 2004 → Sep 1, 2007

About E7070

E7070 is a phase 2 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00165880. Target conditions include Metastatic Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Breast Cancer were approved

Approved (20) Terminated (8) Active (0)
EnzalutamideAstellas PharmaApproved
EnzalutamideAstellas PharmaApproved
EnzalutamideAstellas PharmaApproved
Enfortumab VedotinAstellas PharmaApproved
EligardAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT00165867Phase 2Completed
NCT00165594Phase 1/2Terminated
NCT00165880Phase 2Terminated
NCT00080197Phase 2Completed
NCT00165854Phase 2Completed
NCT00059735Phase 2Completed

Competing Products

20 competing products in Metastatic Breast Cancer

See all competitors